OptimDosing

Combination Oncology

Overview: Combination oncology therapies—targeted agents, immunotherapies, cytotoxics, and supportive drugs—have redefined cancer care but introduced immense dosing complexity. Standard per-agent rules don’t account for synergistic toxicity, cumulative dose exposure, or individualized tolerability.

Problem: Over 70% of oncology patients receive multi-agent regimens during treatment. Clinical trials typically optimize per-agent doses, leaving combinations managed through manual judgment and reactive toxicity monitoring. This creates inefficiencies, excess adverse events, and missed efficacy gains.

Opportunity: Pharma and biotech companies need dose-optimization intelligence that supports adaptive trials, post-marketing analysis, and real-world combination safety modeling.

OptimDosing’s Approach: Our patented logic engine ingests patient-level data (labs, organ function, toxicity history) and population-level evidence to fit individualized dosing models. The engine outputs optimized doses, safety bounds, and rationale artifacts suitable for regulatory documentation.

Value for Partners: Accelerate combination therapy development using model-driven dose recommendations.Support adaptive or basket trial designs with transparent dose logic.Enable retrospective analysis of real-world dosing outcomes across combinations.

Selected references: Mokhtari RB et al., *Cancers (Basel)*, 2017; Chen EY et al., *The Oncologist*, 2025.

Contact: licensing@optimdosing.com • *Patented multi-drug dosing intelligence ready for partnership.*